A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3

Vaccine

Volumn 18, Issue 14, 2000, Pages 1359-1366

  Tao, Tao ^a   Davoodi, Fatemah ^a   Cho, Chris J ^a   Skiadopoulos, Mario H ^a   Durbin, Anna P ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chimeric; Immunization schedule; Live attenuated; Parainfluenza virus; Recombinant; Vaccine

Indexed keywords

HEMAGGLUTININ; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HAMSTER; IMMUNOGENICITY; INOCULATION; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; TEMPERATURE SENSITIVE MUTANT; VACCINATION; VACCINE PRODUCTION; VIRUS GENE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; CRICETINAE; EVALUATION STUDIES; HEMAGGLUTININS; IMMUNIZATION; MESOCRICETUS; NEURAMINIDASE; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 2, HUMAN; PARAINFLUENZA VIRUS 3, HUMAN; RECOMBINANT FUSION PROTEINS; RESPIROVIRUS INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 0033981784     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00406-5     Document Type: Article

References (33)

1. Murphy B.R., Prince G.A., Collins P.L., Van Wyke Coelingh K., Olmsted R.A., Spriggs M.K., et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11:1988;1-15.
2. Collins P.L., Chanock R.M., McIntosh K., et al. Parainfluenza viruses. Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Melnick J.L., Monath T.P., et al. Fields virology. 3rd ed. 1996;1205-1243 Lippincott-Raven Publishers, Philadelphia.
3. Karron R.A., Wright P.F., Newman F.K., Makhene M., Thompson J., Samorodin R., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1995;1445-1450.
4. Karron R.A., Wright P.F., Hall S.L., Makhene M., Thompson J., Burns B.A., et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic and phenotypically stable in infants and children. J. Infect. Dis. 171:1995;1107-1114.
5. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr. Infect. Dis. J. 15:1996;650-654.
6. Belshe R.B., Hissom F.K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol. 10:1982;235-242.
7. Belshe R.B., Van Voris L.P., Mufson M.A., Buynak E.B., McLean A.A., Hilleman M.A. Comparison of enzyme-linked immunosorbent assay and neutralization techniques for measurement of antibody to respiratory syncytial virus: implications for parenteral immunization with live virus vaccine. Infect. Immun. 37:1982;160-165.
8. Crookshanks F.K., Belshe R.B. Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters. J. Med. Virol. 13:1984;243-249.
9. Clements M.L., Belshe R.B., King J., Newman F., Westblom T.U., Tierney E.L., et al. Evaluation of bovine, cold-adapted human and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J. Clin. Microbiol. 29:1991;1175-1182.
10. Hall S.L., Stokes A., Tierney E.L., London W.T., Belshe R.B., Newman F.C., et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:1992;173-184.
11. Durbin A.P., Hall S.L., Siew J.W., Whitehead S.S., Collins P.L., Murphy B.R. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology. 235:1997;323-332.
12. Hoffman M.A., Banerjee A.K. An infectious clone of human parainfluenza virus type 3. J. Virol. 71:1997;4272-4277.
13. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72:1998;1762-1768.
14. Skiadopoulos M.H., Surman S., Tatem J.M., Paschalis M., Wu S.L., Udem S.A., et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73:1999;1374-1381.
15. Tao T., Durbin A.P., Whitehead S.S., Davoodi F., Collins P.L., Murphy B.R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J. Virol. 72:1998;2955-2961.
16. Tao T., Skiadopoulos M.H., Durbin A.P., Davoodi F., Collins P.L., Murphy B.R. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine. 17:1999;1100-1108.
17. Montagnon B.V.-F.J. Experience with the Vero cell line. Brown F.G.E., Horaud F., Petricciani J. Safety of biological products prepared from mammalian cell culture. 1998;119-223 Karger, Basel, Sweden.
18. Murphy B.R., Richman D.D., Chalhub E.G., Uhlendorf C.P., Baron S., Chanock R.M. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect. Immun. 12:1975;62-68.
19. Connors M., Crowe J.E. Jr., Firestone C.-Y., Murphy B.R., Collins P.L. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology. 208:1995;478-484.
20. Coelingh K.J., Winter C.C., Murphy B.R., Rice J.M., Kimball P.C., Olmsted R.A., et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J. Virol. 60:1986;90-96.
21. Cook K.M., Andrews B.E., Fox H.H., Turner H.C., James W.D., Chanock R.M. Antigenic relationships among the "newer" myxoviruses (parainfluenza). Am. J. Hyg. 69:1959;250-264.
22. Cook K.M., Chanock R.M. In vivo antigenic studies of parainfluenza viruses. Am. J. Hyg. 77:1963;150-159.
23. Ray R., Matsuoka Y., Burnett T.L., Glaze B.J., Compans R.W. Human parainfluenza virus induces a type-specific protective immune response. J. Infect. Dis. 162:1990;746-749.
24. Chambers T., Nestorowicz A., Mason P., Rice C. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:1999;3095-3101.
25. Lai C., Bray M., Men R., Cahour A., Chen W., Kawano H., et al. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Virol. 10:1998;173-179.
26. Collins P.L., McIntosh K., Chanock R.M., et al. Respiratory syncytial virus. Fields B.N., Knipe D.M., Howley P.M., Chanock R.M., Melnick J.L., Monath T.P., et al. Fields virology. 3rd ed. 1996;1313-1352 Lippincott-Raven, Philadelphia.
27. Reed G., Jewett P.H., Thompson J., Tollefson S., Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 175:1997;807-813.
28. Karron R.A., Steinhoff M.C., Subbarao E.K., Wilson M.H., Macleod K., Clements M.L., et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr. Infect. Dis. J. 14:1995;10-16.
29. Murphy B.R., Alling D.W., Snyder M.H., Walsh E.E., Prince G.A., Chanock R.M., et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:1986;894-898.
30. Marx A., Torok T., Holman R., Clarke M., Anderson L. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176:1997;1423-1427.
31. Murphy B.R. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults and elderly adults. Infect. Dis. Clin. Practice. 2:1993;174-181.
32. Steinhoff M.C., Fries L.F., Karron R.A., Clements M.L., Murphy B.R. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J. Clin. Microbiol. 31:1993;836-838.
33. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient and J chain-deficient mice. J. Immunol. 158:1997;1222-1230.